|
Fusion gene ID: 22022 |
FusionGeneSummary for MIR548F1_MET |
Fusion gene summary |
Fusion gene information | Fusion gene name: MIR548F1_MET | Fusion gene ID: 22022 | Hgene | Tgene | Gene symbol | MIR548F1 | MET | Gene ID | 100302192 | 8731 |
Gene name | microRNA 548f-1 | RNA guanine-7 methyltransferase | |
Synonyms | MIR548F-1|MIRN548F1|hsa-mir-548f-1 | CMT1|CMT1c|MET|Met|RG7MT1|cm1p|hCMT1|hMet | |
Cytomap | 10q21.1 | 18p11.21 | |
Type of gene | ncRNA | protein-coding | |
Description | - | mRNA cap guanine-N7 methyltransferaseRNA (guanine-7-) methyltransferasehcm1pmRNA (guanine-7-)methyltransferasemRNA (guanine-N(7)-)-methyltransferasemRNA cap methyltransferase | |
Modification date | 20180329 | 20180523 | |
UniProtAcc | P08581 | ||
Ensembl transtripts involved in fusion gene | ENST00000408667, | ENST00000397752, ENST00000318493, ENST00000436117, ENST00000495962, ENST00000539704, | |
Fusion gene scores | * DoF score | 4 X 5 X 1=20 | 11 X 10 X 9=990 |
# samples | 7 | 20 | |
** MAII score | log2(7/20*10)=1.8073549220576 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(20/990*10)=-2.30742852519225 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: MIR548F1 [Title/Abstract] AND MET [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | MET | GO:0006370 | 7-methylguanosine mRNA capping | 27422871 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChiTaRS3.1 | U19348 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + | ||
ChiTaRS3.1 | U08818 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3CDS | ENST00000408667 | ENST00000397752 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
intron-3CDS | ENST00000408667 | ENST00000318493 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
intron-intron | ENST00000408667 | ENST00000436117 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
intron-intron | ENST00000408667 | ENST00000495962 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
intron-intron | ENST00000408667 | ENST00000539704 | MIR548F1 | chr1 | 186337018 | - | MET | chr7 | 116414931 | + |
Top |
FusionProtFeatures for MIR548F1_MET |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MIR548F1 | MET |
Lectin that binds to various sugars: galactose > mannose= fucose > N-acetylglucosamine > N-acetylgalactosamine(PubMed:10224141). Acts as a chemoattractant, probably involved inthe regulation of cell migration (PubMed:28301481).{ECO:0000269|PubMed:10224141, ECO:0000269|PubMed:28301481}. | Receptor tyrosine kinase that transduces signals fromthe extracellular matrix into the cytoplasm by binding tohepatocyte growth factor/HGF ligand. Regulates many physiologicalprocesses including proliferation, scattering, morphogenesis andsurvival. Ligand binding at the cell surface inducesautophosphorylation of MET on its intracellular domain thatprovides docking sites for downstream signaling molecules.Following activation by ligand, interacts with the PI3-kinasesubunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.Recruitment of these downstream effectors by MET leads to theactivation of several signaling cascades including the RAS-ERK,PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation isassociated with the morphogenetic effects while PI3K/AKTcoordinates prosurvival effects. During embryonic development, METsignaling plays a role in gastrulation, development and migrationof muscles and neuronal precursors, angiogenesis and kidneyformation. In adults, participates in wound healing as well asorgan regeneration and tissue remodeling. Promotes alsodifferentiation and proliferation of hematopoietic cells. Mayregulate cortical bone osteogenesis (By similarity).{ECO:0000250|UniProtKB:P16056}. Acts as a receptor for Listeria internalin inlB,mediating entry of the pathogen into cells. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for MIR548F1_MET |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for MIR548F1_MET |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for MIR548F1_MET |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | MET | P08581 | DB08865 | Crizotinib | Hepatocyte growth factor receptor | small molecule | approved |
Tgene | MET | P08581 | DB08875 | Cabozantinib | Hepatocyte growth factor receptor | small molecule | approved|investigational |
Top |
RelatedDiseases for MIR548F1_MET |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | MET | C1336839 | Type 1 Papillary Renal Cell Carcinoma | 5 | UNIPROT |
Tgene | MET | C0007131 | Non-Small Cell Lung Carcinoma | 4 | CTD_human |
Tgene | MET | C0001418 | Adenocarcinoma | 2 | CTD_human |
Tgene | MET | C0004352 | Autistic Disorder | 2 | CTD_human |
Tgene | MET | C0027627 | Neoplasm Metastasis | 2 | CTD_human |
Tgene | MET | C0038356 | Stomach Neoplasms | 2 | CTD_human |
Tgene | MET | C0004114 | Astrocytoma | 1 | CTD_human |
Tgene | MET | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
Tgene | MET | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
Tgene | MET | C0009241 | Cognition Disorders | 1 | CTD_human |
Tgene | MET | C0014859 | Esophageal Neoplasms | 1 | CTD_human |
Tgene | MET | C0017636 | Glioblastoma | 1 | CTD_human |
Tgene | MET | C0019189 | Hepatitis, Chronic | 1 | CTD_human |
Tgene | MET | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
Tgene | MET | C0023904 | Liver Neoplasms, Experimental | 1 | CTD_human |
Tgene | MET | C0024121 | Lung Neoplasms | 1 | CTD_human |
Tgene | MET | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
Tgene | MET | C0027819 | Neuroblastoma | 1 | CTD_human |
Tgene | MET | C0029463 | Osteosarcoma | 1 | CTD_human |
Tgene | MET | C0036341 | Schizophrenia | 1 | CTD_human |
Tgene | MET | C0037199 | Sinusitis | 1 | CTD_human |
Tgene | MET | C0345967 | Malignant mesothelioma | 1 | CTD_human |
Tgene | MET | C0919267 | ovarian neoplasm | 1 | CTD_human |
Tgene | MET | C1876165 | Copper-Overload Cirrhosis | 1 | CTD_human |
Tgene | MET | C2239176 | Liver carcinoma | 1 | CTD_human;HPO;UNIPROT |
Tgene | MET | C4084709 | DEAFNESS, AUTOSOMAL RECESSIVE 97 | 1 | UNIPROT |